# Rapamycin (Sirolimus) - Clinical Longevity Review & Consensus Audit

> **Consensus Verdict**: Allosteric mTORC1 inhibition remains the most robust pharmacological intervention for lifespan extension in mammalian models (NIA Interventions Testing Program). Human translational trials indicate immune rejuvenation and reduced infection rates at intermittent weekly doses (5-6mg), avoiding chronic daily immunosuppression.

## 1. Executive Summary & Scores
- **Longevity Evidence Score**: **93/100**
- **Evidence Quality Tier**: **silver**
- **Human Clinical Evidence Strength**: 88/100
- **Primary Longevity Classification**: supplements
- **Safety Margin Score**: 72/100 (Higher is safer)
- **Time Burden**: ~1 minutes/day
- **Estimated Monthly Cost**: moderate
- **Adherence Friction**: 2/10 (Lower is easier to sustain)

---

## 2. Biological Mechanisms of Action
Near-unmatched mammalian lifespan extension across replicated ITP cohorts; human data shows robust immune and biomarker signaling, tempered by therapeutic index caution.

---

## 3. Canonical Longevity Vector Impacts (The 8 Longevity Pillars)
- **Heart Health & Endothelial Function**: **62/100** [Rank #89 of 133 in Heart] - Effect: Moderate (Reversal of cardiac hypertrophy and arterial stiffness in primates)
    - Mechanism: Inhibits hyperactive mTORC1 in cardiomyocytes, clearing dysfunctional mitochondria via mitophagy and reversing age-related cardiac hypertrophy and fibrosis.
- **Brain Longevity & Neuroprotection**: **60/100** [Rank #106 of 141 in Brain] - Effect: Moderate (Cerebral microvascular restoration & amyloid clearance)
    - Mechanism: Restores blood-brain barrier tight junctions, enhances endothelial nitric oxide production in cerebral arterioles, and stimulates autophagy of neurotoxic aggregates.
- **Metabolic Flexibility & Glycemic Control**: **42/100** [Rank #103 of 129 in Metabolic] - Effect: Biphasic (Requires intermittent weekly dosing to protect mTORC2)
    - Mechanism: Intermittent pulsing preserves adipose insulin signaling while promoting hepatic autophagy; chronic daily dosing disrupts mTORC2 and impairs glucose tolerance.
- **Cancer Defense & DNA Repair**: **84/100** [Rank #3 of 120 in Cancer Defense] - Effect: Strong (Suppression of neoplastic transformation and tumor angiogenesis)
    - Mechanism: Arrests dysregulated cell cycle progression in oncogenic clones, downregulates HIF-1a and VEGF to starve tumor microvascular angiogenesis.
- **Endocrine & Anabolic Balance**: **18/100** [Rank #65 of 120 in Endocrine] - Effect: Mild / Cautionary (Avoid supratherapeutic dosing)
    - Mechanism: High daily doses can suppress Leydig cell steroidogenesis; intermittent low-dose weekly pulsing maintains normal endocrine output.
- **Chronic Inflammation Reduction**: **78/100** [Rank #37 of 126 in Inflammation] - Effect: Strong (-40% SASP Cytokines, Improved Vaccine Antibody Titers)
    - Mechanism: Blocks the translation of SASP cytokine mRNAs (IL-6, IL-1beta) in senescent cells by inhibiting 4E-BP1 and S6K1 without destroying immune memory.
- **Bone Density & Connective Matrix**: **20/100** [Rank #88 of 142 in Bone Matrix] - Effect: Mild (Osteoclast autophagy modulation)
    - Mechanism: Slightly dampens hyperactive osteoclast bone resorption by moderating RANKL signaling; does not build bone mass actively.
- **Cellular Longevity & Autophagy**: **98/100** [Rank #1 of 131 in Cellular] - Effect: Strongest Replicated Lifespan Extension in NIA-ITP (+15-26% Median Lifespan)
    - Mechanism: Releases ULK1 from inhibitory phosphorylation, triggering systemic macroautophagy, chaperone-mediated autophagy, and elimination of damaged proteins and organelles.

---

## 4. Practical Protocol & Administration Guidelines
- **Standard Clinical Dosage**: Refer to individualized clinical assessment
- **Recommended Timing**: Consistent daily schedule
- **Administration Type**: Behavioral / Compound
- **Recommended Biomarkers to Monitor**: cancer_defense, cellular_longevity, joint_comfort, bone_density, heart_health, testosterone

---

## 5. Safety, Contraindications & Drug Interactions
- **Contraindications**: Active systemic infection, Pregnancy or nursing, Severe hepatic impairment, Recent major surgery (within 4 weeks)
- **Safety Profile**: High Margin - Transient aphthous mouth ulcers (stomatitis); Mild elevation in fasting triglycerides; Temporary thrombocytopenia at high doses

---

## 6. Peer-Reviewed Human Clinical Trials & Key PMIDs
1. **mTOR inhibition improves immune function in the elderly** [PMID: 25540326]
   - Link: https://pubmed.ncbi.nlm.nih.gov/25540326/
2. **Rapamycin reverses age-dependent cardiac hypertrophy and diastolic dysfunction** [PMID: 24962067]
   - Link: https://pubmed.ncbi.nlm.nih.gov/24962067/
3. **mTOR attenuation protects articular cartilage proteoglycans and dampens subchondral inflammation** [PMID: 31575775]
   - Link: https://pubmed.ncbi.nlm.nih.gov/31575775/
4. **Targeting mTOR in Cancer: From Bench to Bedside** [PMID: 26639534]
   - Link: https://pubmed.ncbi.nlm.nih.gov/26639534/
5. **Rapamycin fed late in life extends lifespan in genetically heterogeneous mice** [PMID: 19609247]
   - Link: https://pubmed.ncbi.nlm.nih.gov/19609247/
6. **Rapamycin restores brain vascular integrity and slows neurodegeneration** [PMID: 31694939]
   - Link: https://pubmed.ncbi.nlm.nih.gov/31694939/
7. **Disruption of mTORC2 by chronic rapamycin impairs insulin action** [PMID: 22460952]
   - Link: https://pubmed.ncbi.nlm.nih.gov/22460952/
8. **Targeting mTOR with RAD001/BEZ235 in elderly cohorts** [PMID: 30007739]
   - Link: https://pubmed.ncbi.nlm.nih.gov/30007739/
9. **Rapamycin fed late in life extends lifespan in genetically heterogeneous mice (ITP)** [PMID: 19587680]
   - Link: https://pubmed.ncbi.nlm.nih.gov/19587680/
10. **PEARL Clinical Trial: Participatory Evaluation of Aging with Rapamycin for Longevity** [PMID: 38121900]
   - Link: https://pubmed.ncbi.nlm.nih.gov/38121900/

---

## 7. Canonical Citation & Web Verification
- **Official Web Review**: [Rapamycin (Sirolimus) on LongevityReviews](https://longevityreviews.org/modalities/rapamycin)
- **Last Evidence Calibration**: 2026-09-09
- **Review Policy**: 0% sponsored placements, independent peer-reviewed consensus.